Bansisons Tea Industries Limited, now operating as Novyra Pharmachem Limited, has announced its unaudited financial results for the third quarter ended December 31, 2025. The company's Board of Directors approved these results during their meeting held on January 26, 2026, at the registered office in Surat, Gujarat.

Financial Performance Overview

The company reported challenging financial performance for the quarter, with no revenue generation from operations. The financial results show a net loss of ₹1.15 lakhs for Q3 FY26, representing a deterioration from the ₹0.88 lakhs loss recorded in the corresponding quarter of the previous year.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, the company's performance showed mixed results compared to the previous year. While other income increased to ₹6.31 lakhs from nil in the corresponding period last year, total expenses also rose significantly.

Expense Structure and Key Metrics

The company's expense structure for Q3 FY26 comprised employee benefit expenses of ₹0.39 lakhs, depreciation and amortisation expense of ₹0.73 lakhs, and other expenses of ₹0.03 lakhs. The increase in depreciation expenses indicates potential capital investments or asset additions during the period.

Earnings Per Share Performance:

• Basic EPS for Q3 FY26: ₹(0.02)
• Diluted EPS for Q3 FY26: ₹(0.02)
• Nine-month EPS: ₹(0.03)

The company's paid-up equity share capital stands at ₹630.00 lakhs as of December 31, 2025, with a face value of ₹10.00 per share.

Corporate Governance and Compliance

The financial results were reviewed by the Audit Committee before approval by the Board of Directors. The statutory auditors D G M S & Co., Chartered Accountants, conducted a limited review of the unaudited results. The results have been prepared in accordance with Indian Accounting Standard 34 - Interim Financial Reporting, as prescribed under Section 133 of the Companies Act, 2013.

The Board meeting commenced at 5:30 PM and concluded at 7:00 PM on January 26, 2026, with Director Hiren Dhirajlal Shah (DIN: 09842161) signing the results on behalf of the company.

Bansisons Tea Industries Limited has successfully completed its postal ballot process, with shareholders unanimously approving all three proposed resolutions. The company's transformation from tea operations to pharmaceutical manufacturing has received complete shareholder backing through the e-voting process.

Postal Ballot Results Summary

The voting results demonstrate overwhelming shareholder support for the company's strategic transformation:

Key Approved Resolutions

Resolution 1: Object Clause Modification

Shareholders approved the change of Object Clause in the Memorandum of Association, enabling the company to pivot from tea operations to pharmaceutical manufacturing, research, and chemical activities.

Resolution 2: Name Change

The proposal to change the company name from "Bansisons Tea Industries Limited" to "Novyra Pharmachem Limited" received unanimous approval, reflecting the new business direction.

Resolution 3: Asset Disposal

Shareholders endorsed the disposal of company assets under Section 180(1)(a) of the Companies Act, 2013, facilitating the business transformation.

Voting Process Details

The e-voting process was conducted through NSDL's platform from November 29 to December 29. Out of 27,898 total shareholders on record date, 35 shareholders participated in the voting process, representing 805,000 votes or 12.72% of outstanding shares.

The scrutinizer Mrs. Rupal Patel, Practicing Company Secretary, certified the voting results, confirming that all resolutions were passed with the requisite majority. The company has now received formal approval to proceed with its strategic transformation into the pharmaceutical sector.